As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly 15 million people, or about 12% of the U.S. population, have used injectable medications like Ozempic and Wegovy to slim down this season.
We report on the growing popularity of these GLP-1 medications, how they work, and the medical concerns tied to their use.
The drugs—Wegovy and Ozempic, which contain the active ingredient semaglutide, and Zepbound and Mounjaro, which contain tirzepatide—are administered through once-weekly injections. Originally developed for type 2 diabetes, these medications are now widely used off-label or FDA-approved for weight loss.
They work by mimicking a hormone called GLP-1, which stimulates insulin production in the pancreas and slows digestion. This helps people feel fuller for longer, curbing appetite and reducing overall calorie intake. Clinical studies show the shots can lead to 15% to 20% weight loss, along with a 20% reduction in cardiovascular risk.
Still, doctors are urging caution.
“Patients may see dramatic weight loss, but they could also be losing critical muscle mass if not closely monitored,” said Dr. Mickey Seger, chief of bariatric surgery at Methodist Specialty and Transplant Hospital in San Antonio. “The scale only tells part of the story.”
Seger emphasizes the need for medical supervision, particularly when using these drugs long-term. A proper diet, rich in nutrients and protein, is key to preserving muscle and maintaining overall health.
Looking ahead, Seger says the pharmaceutical pipeline is full, with more than 30 new weight-loss drugs in development. That means patients may soon have even more options—but also more reason to seek expert guidance.